Gaming accessory company Turtle Beach Corporation (HEAR) will report fourth quarter financial results on March 14, Thursday, after the closing bell. The company, which makes headphones for gaming devices, is expected to report earnings of $1.31 per share on revenues of $110.3 million.
During the same quarter last year, the company had reported earnings of 29 cents per share on revenues of $79.7 million.
The analyst projection for the fourth quarter represents a 37% jump in net sales, on the company’s strong positioning in a healthy gaming audio market. The launch of numerous new products, including the high-performance Turtle Beach Battle Buds, is likely to ensure Turtle jumps following the earnings announcement.
The company continues to maintain a dominant status in its core regions of operation – Europe and North America – thanks to the increasing acceptance for eSports. The favorable market dynamics have given Turtle Beach enough confidence to venture into new markets that hold potential. Look out for any management comments regarding the company’s expansion strategy in 2019.
For the past five years, the company’s EPS has grown at a rate of 16.2%. For the next five years, analysts expect it the growth rate to be around 18%.
Read: Nvidia’s 7-bn purchase of Mellanox Technologies to help boost data center biz
The stock has soared over 700% in the trailing 52 weeks. Since the start of this year, though, it has been mostly flattish.
The stock has a 12-month average price target of $29.5, suggesting 88% upside from the last close.
The company’s Swiss rival Logitech International (LOGI) will report its quarterly results next month.
Earnings Calendar: Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on